Immunotherapy News and Research

Latest Immunotherapy News and Research

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient.

15 Nov 2024

Customizable biological sensors activate cancer immunotherapy only in tumor environments

Most cancer treatments – from chemotherapies to engineered immune cells – have a host of side effects, in large part because they affect healthy cells in the body at the same time as targeting tumor cells.

15 Nov 2024

New drug strategy reverses resistance to immunotherapy in pancreatic cancer

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and Oregon Health & Science University.

14 Nov 2024

CAR T cell therapy breakthroughs bring new hope for treating solid tumors

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor environments, with promising clinical results.

13 Nov 2024

UBC researchers develop coating to make medical devices safer for patients

University of B.C. researchers have developed a groundbreaking coating that could make medical devices safer for millions of patients, reducing the risks associated with blood clots and dangerous bleeding.

12 Nov 2024

Georgia Tech researchers create lab-grown models of human immune systems

To better understand why some cancer patients struggle to fight off infections, Georgia Tech researchers have created tiny lab-grown models of human immune systems.

12 Nov 2024

Early genomic profiling improves cancer treatment outcomes

New real-world data from Providence, Illumina, and Microsoft Research reveals that Comprehensive Genomic Profiling (CGP), when done early in a cancer patient's diagnosis, leads to better personalized treatment and patient outcomes.

12 Nov 2024

New treatment combination improves outcomes for small cell bladder and prostate cancer patients

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

12 Nov 2024

Key reason why some cancers do not respond to immunotherapy identified

Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target for improved cancer treatments.

12 Nov 2024

Nomic® and Parker Institute for Cancer Immunotherapy (PICI) launch large-scale protein profiling to investigate immunotherapy responses in RADIOHEAD study

Nomic Bio and PICI collaborate to quantify protein biomarkers in cancer immunotherapy, enhancing understanding of patient responses and treatment resistance.

From Nomic 12 Nov 2024

Patient-derived organoids: Transforming cancer research and personalized medicine

Patient-derived organoids (PDOs) are revolutionizing cancer research, enhancing drug testing and personalized treatment through advanced 3D modeling techniques.

12 Nov 2024

Researchers develop new antibody with potential to treat several types of cancer

Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer.

11 Nov 2024

VANCE trial marks milestone in t cell therapy for solid tumors

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.

11 Nov 2024

Cleveland Clinic presents new findings on triple-negative breast cancer vaccine

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

8 Nov 2024

New approach reinvigorates exhausted T cells to improve tumor control

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T cells - which have lost their cancer-fighting oomph - consume this lactic acid, which further saps their energy, according to new research from the University of Pittsburgh and UPMC Hillman Cancer Center.

8 Nov 2024

MD Anderson launches new institute for advancing cell therapy

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.

8 Nov 2024